Windlas Biotech Ltd

BSE
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

Start SIP in Windlas Biotech Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
112.65% Gain from 52W Low
8.7
TTM PE Ratio
Below industry Median
21.9
Price to Book Ratio
Below industry Median
2.9
Dividend yield 1yr %
Below industry Median
0.7
TTM PEG Ratio
PEG TTM is much higher than 1
1.5
RSI
RSI is mid-range
53.5
MFI
MFI is mid-range
54.6

Windlas Biotech Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Windlas Biotech Ltd shareholding Pattern

Promoter
62.8%
Foreign Institutions
1.2%
Mutual Funds
10.4%
Domestic Institutions
11.8%
Public
24.2%
Promoter
62.8%
Foreign Institutions
1.4%
Mutual Funds
10.4%
Domestic Institutions
11.7%
Public
24.1%
Promoter
62.8%
Foreign Institutions
0.8%
Mutual Funds
10.4%
Domestic Institutions
11.5%
Public
24.8%
Promoter
62.8%
Foreign Institutions
0.8%
Mutual Funds
10.5%
Domestic Institutions
11.5%
Public
24.8%
Promoter
62.4%
Foreign Institutions
1.3%
Mutual Funds
10.6%
Domestic Institutions
11.6%
Public
24.7%
Promoter
60.8%
Foreign Institutions
1.4%
Mutual Funds
11.4%
Domestic Institutions
12.2%
Public
25.6%

Windlas Biotech Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
536.30
10Day EMA
533.50
12Day EMA
533.60
20Day EMA
534.60
26Day EMA
534.80
50Day EMA
529.50
100Day EMA
504.90
200Day EMA
453.90
5Day SMA
534.80
10Day SMA
525.90
20Day SMA
539.50
30Day SMA
540.10
50Day SMA
536.50
100Day SMA
512.70
150Day SMA
471.90
200Day SMA
444.30
Delivery & Volume
Resistance & Support
547.60
Pivot
Resistance
First Resistance
561.20
Second Resistance
579.60
Third Resistance
593.20
Support
First Support
529.20
Second support
515.60
Third Support
497.20
Relative Strength Index
53.47
Money Flow Index
54.64
MACD
-1.14
MACD Signal
-1.66
Average True Range
23.39
Average Directional Index
13
Rate of Change (21)
2.51
Rate of Change (125)
29.98
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Bliss GVS Pharma Ltd.
1146.89
71
148.95
Jagsonpal Pharmaceuticals Ltd.
944.89
270.05
513.9
Lincoln Pharmaceuticals Ltd.
1155.52
365.4
754.25
Beta Drugs Ltd.
-
-
-
Bharat Parenterals Ltd.
-
-
-
Remus Pharmaceuticals Ltd.
-
-
-

Windlas Biotech Ltd Company background

Founded in: 2001
Managing director: Hitesh Windlass
Windlas Biotech Ltd (formerly known as Windlas Biotech Private Limited) was incorporated in the year 2001. The Company provides pharmaceutical development services, largescale manufacturing services and authentic yet affordable products to its customers and consumers around the world.The company has stateoftheart manufacturing plant facilities located in Dehradun, Uttarakhand, India. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical, pharmaceutical and Ayurvedic products to serve the semiurban and rural communities at affordable prices. Apart from this, the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products domestic trade generics and overthecounter (OTC) brands and exports.The company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries. Moreover, the company has significant experience in developing and manufacturing generic fixed dose combinations. Its focus has currently been in launching new complex generic products in the chronic therapeutic category linked to lifestyle related disorders.The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drugdevice combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and lowsolubility products. Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible. To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and RD, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.
Read More

Windlas Biotech Ltd FAQs

The past 1-year return of Windlas Biotech Ltd [WINDLAS] share was 104.51. The Windlas Biotech Ltd [WINDLAS] share hit a 1-year low of Rs. 260 and a 1-year high of Rs. 590.

The Mutual Fund Shareholding was 10.37% at the end of .

You can easily buy Windlas Biotech Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage